Mahshad Ghezelbash
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mahshad Ghezelbash has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Alireza Shakeri
Anesthesiology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
1 shared publication - Anna Ghorbani Doshantapeh
Department of Hematology-Medical Oncology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
1 shared publication - Ardeshir Tajbakhsh
Clinical Research Development Center, Imam Hossein Educational Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
1 shared publication - Behrooz Fakhar
Department of Anesthesia and Intensive Care, Faculty of Medicine, AJA University of Medical Sciences, Tehran, Iran
1 shared publication - Behrooz Zaman
Department of Anesthesiology and Pain Medicine, Pain Research Center, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
1 shared publication - Farinaz Fattahi
Department of Emergency Medicine, School of Medicine, Milad Hospital, Isfahan University of Medical Sciences, Isfahan, Iran
1 shared publication
Latest Publications
- Open Access
- 30 June 2026
- Published by Brieflands in Anesthesiology and Pain Medicine
- Vol. 16 (3) , e172772
Effect of Sub-antagonist Doses of Naloxone as an Adjuvant to Ropivacaine on the Onset and Quality of Axillary Brachial Plexus Block in Patients Undergoing Forearm and Hand Surgery: A Randomized Double-Blind Clinical Trial
Background: Axillary brachial plexus block (ABPB) is the preferred regional anesthetic technique for forearm and hand surgery. Naloxone at sub-antagonist doses may paradoxically enhance local anesthetic effects through selective opioid receptor modulation; however, the optimal dose and its clinical benefit in ABPB with ropivacaine remain unclear. Objectives: This study aimed to compare the effects of ultra-low-dose naloxone (0.4 µg), low-dose naloxone (4 µg), and placebo added to 0.5% ropivacaine on block onset, intensity, and postoperative analgesia in patients undergoing elective forearm and hand surgery. To our knowledge, this is the first trial to directly compare two sub-antagonist doses of naloxone as adjuvants to ropivacaine for axillary block. Methods: In this randomized, double-blind clinical trial, 120 patients with American Society of Anesthesiologists (ASA) physical status I or II were allocated equally to three groups: Group 1 (control; ropivacaine plus saline), Group 2 (ropivacaine plus low-dose naloxone, 4 µg), and Group 3 (ropivacaine plus ultra-low-dose naloxone, 0.4 µg). All blocks were performed using combined ultrasound and nerve stimulator guidance. The co-primary outcomes were sensory and motor block onset times. Secondary outcomes included block intensity, visual analog scale (VAS) pain scores during recovery, and the proportion of patients requiring pethidine within 24 hours. Results: All 120 blocks (100%) were clinically successful, with no intraoperative rescue analgesia or conversion to general anesthesia in any group. Motor block onset was significantly faster in Groups 2 and 3 than in Group 1 (P < 0.001); no patient in the naloxone groups required 9 minutes to achieve motor block, compared with 30% in Group 1. Sensory block onset did not differ significantly among groups (P = 0.163). At 30 minutes, VAS scores were lower in both naloxone groups than in Group 1; the overall analysis of variance (ANOVA) result was P < 0.001, and the reported comparison between Group 3 and Group 1 was significant (P < 0.001). The 15-minute difference was not significant after Bonferroni correction. The proportion requiring pethidine within 24 hours was significantly lower in Group 3 than in Group 1, with a risk ratio of 0.52 [95% CI, 0.33 - 0.82] (27.5% vs. 52.5%; P = 0.005). Group 2 had a numerically higher pethidine requirement than Group 1 (62.5% vs. 52.5%), suggesting possible dose-dependent partial receptor antagonism that requires confirmation in future studies. Conclusions: Ultra-low-dose naloxone (0.4 µg) significantly accelerates motor block onset and reduces postoperative pethidine requirements in patients with American Society of Anesthesiologists physical status I or II undergoing elective hand and forearm surgery with ABPB, without adverse effects. Although the 4 µg dose was associated with lower VAS scores at 30 minutes, it did not reduce pethidine requirements and was associated with a nonsignificant increase in the proportion of patients requiring pethidine, consistent with a biphasic dose-response model. These findings highlight the narrow therapeutic margin of perineural naloxone and suggest caution with doses above the ultra-low-dose range, as higher sub-antagonist doses may paradoxically antagonize endogenous analgesic mechanisms.
- 30 June 2026
- Published by Brieflands in Anesthesiology and Pain Medicine
- Vol. 16 (3) , e172772
Open AccessEffect of Sub-antagonist Doses of Naloxone as an Adjuvant to Ropivacaine on the Onset and Quality of Axillary Brachial Plexus Block in Patients Undergoing Forearm and Hand Surgery: A Randomized Double-Blind Clinical Trial
Background: Axillary brachial plexus block (ABPB) is the preferred regional anesthetic technique for forearm and hand surgery. Naloxone at sub-antagonist doses may paradoxically enhance local anesthetic effects through selective opioid receptor modulation; however, the optimal dose and its clinical benefit in ABPB with ropivacaine remain unclear. Objectives: This study aimed to compare the effects of ultra-low-dose naloxone (0.4 µg), low-dose naloxone (4 µg), and placebo added to 0.5% ropivacaine on block onset, intensity, and postoperative analgesia in patients undergoing elective forearm and hand surgery. To our knowledge, this is the first trial to directly compare two sub-antagonist doses of naloxone as adjuvants to ropivacaine for axillary block. Methods: In this randomized, double-blind clinical trial, 120 patients with American Society of Anesthesiologists (ASA) physical status I or II were allocated equally to three groups: Group 1 (control; ropivacaine plus saline), Group 2 (ropivacaine plus low-dose naloxone, 4 µg), and Group 3 (ropivacaine plus ultra-low-dose naloxone, 0.4 µg). All blocks were performed using combined ultrasound and nerve stimulator guidance. The co-primary outcomes were sensory and motor block onset times. Secondary outcomes included block intensity, visual analog scale (VAS) pain scores during recovery, and the proportion of patients requiring pethidine within 24 hours. Results: All 120 blocks (100%) were clinically successful, with no intraoperative rescue analgesia or conversion to general anesthesia in any group. Motor block onset was significantly faster in Groups 2 and 3 than in Group 1 (P < 0.001); no patient in the naloxone groups required 9 minutes to achieve motor block, compared with 30% in Group 1. Sensory block onset did not differ significantly among groups (P = 0.163). At 30 minutes, VAS scores were lower in both naloxone groups than in Group 1; the overall analysis of variance (ANOVA) result was P < 0.001, and the reported comparison between Group 3 and Group 1 was significant (P < 0.001). The 15-minute difference was not significant after Bonferroni correction. The proportion requiring pethidine within 24 hours was significantly lower in Group 3 than in Group 1, with a risk ratio of 0.52 [95% CI, 0.33 - 0.82] (27.5% vs. 52.5%; P = 0.005). Group 2 had a numerically higher pethidine requirement than Group 1 (62.5% vs. 52.5%), suggesting possible dose-dependent partial receptor antagonism that requires confirmation in future studies. Conclusions: Ultra-low-dose naloxone (0.4 µg) significantly accelerates motor block onset and reduces postoperative pethidine requirements in patients with American Society of Anesthesiologists physical status I or II undergoing elective hand and forearm surgery with ABPB, without adverse effects. Although the 4 µg dose was associated with lower VAS scores at 30 minutes, it did not reduce pethidine requirements and was associated with a nonsignificant increase in the proportion of patients requiring pethidine, consistent with a biphasic dose-response model. These findings highlight the narrow therapeutic margin of perineural naloxone and suggest caution with doses above the ultra-low-dose range, as higher sub-antagonist doses may paradoxically antagonize endogenous analgesic mechanisms.
- Open Access
- 25 February 2025
- Published by Maad Rayan Publishing Company in Journal of Nephropathology
- Vol. 14, e27612
Precipitating factors for mortality of individuals with acute kidney injury in ICU; collaboration of nephrologists and intensivists
Acute kidney injury (AKI) is a common and critical condition faced by patients in the intensive care units (ICUs), which significantly increases morbidity and mortality rates among affected individuals. Additionally, individuals in the ICU often present with a multitude of comorbidities, which significantly influence the risk of developing acute renal failure and the associated mortality rates. Common underlying conditions such as hypertension, diabetes, heart disease, and chronic kidney disease (CKD) predispose patients to acute renal failure. Hypertension and diabetes are particularly noteworthy as they distort renal hemodynamics, leading to increased susceptibility to acute renal failure during critical illness. Moreover, older patients consistently exhibit higher mortality rates associated with AKI, as advancing age correlates with deteriorating organ function and increased prevalence of comorbid conditions.
- 25 February 2025
- Published by Maad Rayan Publishing Company in Journal of Nephropathology
- Vol. 14, e27612
Open AccessPrecipitating factors for mortality of individuals with acute kidney injury in ICU; collaboration of nephrologists and intensivists
Acute kidney injury (AKI) is a common and critical condition faced by patients in the intensive care units (ICUs), which significantly increases morbidity and mortality rates among affected individuals. Additionally, individuals in the ICU often present with a multitude of comorbidities, which significantly influence the risk of developing acute renal failure and the associated mortality rates. Common underlying conditions such as hypertension, diabetes, heart disease, and chronic kidney disease (CKD) predispose patients to acute renal failure. Hypertension and diabetes are particularly noteworthy as they distort renal hemodynamics, leading to increased susceptibility to acute renal failure during critical illness. Moreover, older patients consistently exhibit higher mortality rates associated with AKI, as advancing age correlates with deteriorating organ function and increased prevalence of comorbid conditions.
- Open Access
- 22 August 2023
- Published by Maad Rayan Publishing Company in Immunopathologia Persa
- Vol. 11 (1) , e40572
Impact of analgesics on the risk of ovarian cancer; a systematic review and meta-analysis of cohort and case-control studies
Introduction: Ovarian cancer is the sixth leading cancer-related mortality cause in women worldwide. Analgesics may hinder the occurrence of ovarian cancer through inflammation relief. The present study seeks to examine the relationship between analgesic consumption and ovarian cancer risk through a systematic review and meta-analysis. Materials and Methods: PubMed, Scopus, Web of Science, Cochrane databases, and Google Scholar search engines were searched for works published by May 2023 using standard keywords to collect the required data sources. Acquired data were then analyzed in STATA version14, considering a significance level of P < 0.05 in statistical tests. Results: The present meta-analysis comprised 21 studies (14 case-control and 7 cohort studies) performed on 53,755 subjects. Results indicated that taking aspirin reduced the risk of ovarian cancer by 8% (OR: 0.92; 95% CI: 0.87, 0.98), whereas other non-aspirin NSAIDs (non-steroidal anti-inflammatory drugs) did not significantly affect the ovarian cancer risk (OR: 0.91; 95% CI: 0.81, 1.02). Similar results were observed in the case of ibuprofen and acetaminophen, with non-significant relationships between the risk of ovarian cancer and with the consumption of both acetaminophen (OR: 0.95; 95% CI: 0.84, 1.08) and ibuprofen (OR: 0.76; 95% CI: 0.50, 1.14). Furthermore, the duration of analgesic consumption was not significantly linked to the risk of ovarian cancer in the case of all studied drugs. Conclusion: Among aspirin, ibuprofen, acetaminophen, and non-aspirin NSAIDs, only aspirin was found to reduce the risk of ovarian cancer in women while the other studied drugs did not influence the studied risk. However, further research is recommended to confirm the results. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (CRD42023434730) and Research Registry (UIN: reviewregistry1668) websites.
- 22 August 2023
- Published by Maad Rayan Publishing Company in Immunopathologia Persa
- Vol. 11 (1) , e40572
Open AccessImpact of analgesics on the risk of ovarian cancer; a systematic review and meta-analysis of cohort and case-control studies
Introduction: Ovarian cancer is the sixth leading cancer-related mortality cause in women worldwide. Analgesics may hinder the occurrence of ovarian cancer through inflammation relief. The present study seeks to examine the relationship between analgesic consumption and ovarian cancer risk through a systematic review and meta-analysis. Materials and Methods: PubMed, Scopus, Web of Science, Cochrane databases, and Google Scholar search engines were searched for works published by May 2023 using standard keywords to collect the required data sources. Acquired data were then analyzed in STATA version14, considering a significance level of P < 0.05 in statistical tests. Results: The present meta-analysis comprised 21 studies (14 case-control and 7 cohort studies) performed on 53,755 subjects. Results indicated that taking aspirin reduced the risk of ovarian cancer by 8% (OR: 0.92; 95% CI: 0.87, 0.98), whereas other non-aspirin NSAIDs (non-steroidal anti-inflammatory drugs) did not significantly affect the ovarian cancer risk (OR: 0.91; 95% CI: 0.81, 1.02). Similar results were observed in the case of ibuprofen and acetaminophen, with non-significant relationships between the risk of ovarian cancer and with the consumption of both acetaminophen (OR: 0.95; 95% CI: 0.84, 1.08) and ibuprofen (OR: 0.76; 95% CI: 0.50, 1.14). Furthermore, the duration of analgesic consumption was not significantly linked to the risk of ovarian cancer in the case of all studied drugs. Conclusion: Among aspirin, ibuprofen, acetaminophen, and non-aspirin NSAIDs, only aspirin was found to reduce the risk of ovarian cancer in women while the other studied drugs did not influence the studied risk. However, further research is recommended to confirm the results. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (CRD42023434730) and Research Registry (UIN: reviewregistry1668) websites.